Precision NanoSystems To Advance Large-Scale Production Of Nanoparticles With Its NanoAssemblr Blaze System

VANCOUVER, British Columbia, Aug. 18, 2016 /PRNewswire/ -- Precision NanoSystems, Inc. (PNI), a biotechnology company dedicated to helping advance nanotechnology solutions for the molecular understanding and treatment of disease, today officially launches its NanoAssemblr Blaze system.

The NanoAssemblr Blaze from Precision NanoSystems allows for the seamless translation of nanomedicines from discovery to clinical development. The Blaze can manufacture between 10 mL and 1 L per batch.

The NanoAssemblr Blaze moves nanomedicine development from the preliminary stages of formulation screening and iteration onto large batch manufacturing of nanoparticles suitable for toxicology screening and analysis. Based on the proven NanoAssemblr platform, the increase in volume afforded by the Blaze provides a seamless transition without further process development.

"This product is an exciting leap forward for Precision NanoSystems," said James Taylor, CEO and Co-founder of PNI. "We started with our NanoAssemblr Benchtop instrument, which helped researchers develop small batches of precise nanoparticles, but we soon realized we needed to respond to the impetus to scale up production with that same level of accuracy. The NanoAssemblr Blaze does exactly that, without having to re-invent process."

The NanoAssemblr Blaze utilizes the latest microfluidic technology with continuous flow pumping through a proprietary microfluidic cartridge to produce large volumes of identical nanoparticles, between 10 mL and 1 L per batch. The process ensures the self-assembly of uniform particles with controllable and reproducible results.

PNI Chief Operating Officer Euan Ramsay says the system is perfect for nanomedicine candidate selection and early Chemistry, Manufacturing and Controls (CMC) investigation. "The NanoAssemblr Blaze gives scientists the ability to scale up their experiments and accelerate discovery," said Ramsay. "We anticipate a leap forward in research results and thus the ultimate treatment of disease using nanoparticle-based medicine."   

Researchers can now create scalable amounts of nanoparticles with significant cost and labor reductions and with the certainty that the product has been made to the highest of standards. The NanoAssemblr Blaze brings large batch nanoparticle studies in-house, and transfers small or lab-scale formulations seamlessly into large volumes.

About Precision NanoSystems, Inc.
Precision NanoSystems, Inc. (PNI) creates solutions for the discovery, development and manufacture of novel nanoparticles for use as medicines and in medical research. PNI's proprietary NanoAssemblr platform enables the rapid, reproducible, and scalable manufacture of next generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to cells and tissues. PNI builds strategic collaborations with life sciences researchers and pharmaceutical companies to revolutionize healthcare through nanotechnology. Visit

Photo -


To view the original version on PR Newswire, visit:

SOURCE Precision NanoSystems, Inc.

Back to news